ArticleJournal of clinical imaging science2026
CT findings in biomass smoke-associated interstitial lung disease: A retrospective analysis.
Article in Journal of clinical imaging science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Household air pollution from biomass fuel combustion remains a major global health burden, affecting nearly 3 billion people worldwide. Although biomass smoke exposure is a recognized risk factor for chronic airway disease, its role in interstitial lung disease (ILD) is less well defined, and characteristic CT features have not been systematically described in patients without coexisting chronic obstructive pulmonary disease (COPD). Material and Methods: We conducted a retrospective review of 23 patients with biomass smoke exposure and radiographic evidence of ILD, excluding those with alternative ILD etiologies or pre-existing COPD. CT scans were independently assessed by a thoracic radiologist and two pulmonologists for predominant patterns, distributions, and additional findings, with consensus classification. We report proportions with 95% confidence intervals (CIs) and performed exploratory Spearman correlation to assess associations between selected CT features. Results: The cohort (mean age 71.7 years; all females; 96% born outside the United States) most commonly demonstrated reticulation (16/23, 70%; 95% CI, 49-84%), ground-glass opacities (GGO) (15/23, 65%; 95% CI, 45-81%), mosaic attenuation (15/23, 65%; 95% CI, 45-81%), and bronchial wall thickening (14/23, 61%; 95% CI, 41-78%). Abnormalities were typically patchy (18/23, 78%; 95% CI, 58-90%) and peribronchial (13/23, 57%; 95% CI, 37-74%), without consistent apical or basal predominance. Traction bronchiectasis occurred in 12/23 (52%; 95% CI, 33-71%) and lymphadenopathy in 9/23 (39%; 95% CI, 22-59%). Honeycombing (5/23, 22%; 95% CI, 10-42%), centrilobular emphysema (4/23, 17%; 95% CI, 7-37%), nodules (3/23, 13%; 95% CI, 5-32%), cysts (2/23, 9%; 95% CI, 2-27%), tree-in-bud opacities (2/23, 9%; 95% CI, 2-27%), and centrilobular nodularity (1/23, 4%; 95% CI, 1-21%) were uncommon. Exploratory Spearman analyses showed strong associations between mosaic attenuation and bronchial wall thickening (ρ = 0.91) and between peribronchial distribution and mosaic attenuation (ρ = 0.83), with additional positive correlations between mosaic attenuation and bronchiectasis (ρ = 0.70), peribronchial distribution and bronchial wall thickening (ρ = 0.73), bronchial wall thickening and bronchiectasis (ρ = 0.77), bronchiectasis and traction bronchiectasis (ρ = 0.57), and reticulation and traction bronchiectasis (ρ = 0.69). Exploratory Spearman correlation analyses showed strong associations between mosaic attenuation and bronchial wall thickening (ρ = 0.91) and between peribronchial distribution and mosaic attenuation (ρ = 0.83), with additional positive correlations between mosaic attenuation and bronchiectasis (ρ = 0.70), peribronchial distribution and bronchial wall thickening (ρ = 0.73), bronchial wall thickening and bronchiectasis (ρ = 0.77), bronchiectasis and traction bronchiectasis (ρ = 0.57), and reticulation and traction bronchiectasis (ρ = 0.69). Conclusion: Biomass smoke-associated ILD demonstrates a distinctive CT pattern characterized by reticulation, GGOs, and mosaic attenuation with patchy and peribronchial distribution and no clear zonal predominance. Unlike hypersensitivity pneumonitis, it lacks centrilobular nodularity. Compared with idiopathic pulmonary fibrosis (IPF), it shows less extensive subpleural honeycombing, more peribronchial involvement, and no consistent basal predominance. These distinctions may improve recognition of biomass smoke-associated ILD in exposed patients. Further prospective studies are needed to validate these findings and clarify their prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.